15-38351302-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_152594.3(SPRED1):c.973C>T(p.Arg325*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000124 in 1,613,860 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_152594.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- Legius syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics, Genomics England PanelApp, ClinGen, PanelApp Australia, G2P, Labcorp Genetics (formerly Invitae)
 
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes   AF:  0.00000658  AC: 1AN: 152044Hom.:  0  Cov.: 32 show subpopulations 
GnomAD4 exome  AF:  6.84e-7  AC: 1AN: 1461816Hom.:  0  Cov.: 31 AF XY:  0.00  AC XY: 0AN XY: 727206 show subpopulations 
Age Distribution
GnomAD4 genome   AF:  0.00000658  AC: 1AN: 152044Hom.:  0  Cov.: 32 AF XY:  0.00  AC XY: 0AN XY: 74240 show subpopulations  ⚠️ The allele balance in gnomAD version 4 Genomes is significantly skewed from the expected value of 0.5. 
ClinVar
Submissions by phenotype
Legius syndrome    Pathogenic:2 
This sequence change creates a premature translational stop signal (p.Arg325*) in the SPRED1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 120 amino acid(s) of the SPRED1 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Legius syndrome (PMID: 17704776, 25883013; internal data). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 374301). Algorithms developed to predict the effect of variants on gene product structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects SPRED1 function (PMID: 17704776). This variant disrupts a region of the SPRED1 protein in which other variant(s) (p.Gly385Ilefs*20, p.Arg349Glyfs*11) have been determined to be pathogenic (PMID: 17704776, 21089071, 21649642). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
This de novo pathogenic variant has been previously reported as disease-causing [PMID 17704776] and was found in our laboratory in a 6 month old female with delayed motor milestones, generalized hypotonia with tracheostomy, micrognathia, camptodactyly and overriding toes, failure to thrive, patent foramen ovale, and hemangioma on the left hand. A homozygous pathogenic variant in MEGF10 (NM_032446.2, c.1557delA) was reported in the same individual. -
Male infertility with spermatogenesis disorder    Pathogenic:1 
In addition, the same case carried one additional variant: TP63 c.1283C>T p.P428L, indicating a digenic effect. -
Neurofibromatosis, type 1    Pathogenic:1 
- -
Cardiovascular phenotype    Pathogenic:1 
The p.R325* pathogenic mutation (also known as c.973C>T), located in coding exon 7 of the SPRED1 gene, results from a C to T substitution at nucleotide position 973. This changes the amino acid from an arginine to a stop codon within coding exon 7. This mutation was originally identified in a patient with neurofibromatosis 1 (NF1)-like phenotype (Brems H et al. Nat. Genet., 2007 Sep;39:1120-6) and subsequently reported in multiple patients with NF1 features (Messiaen L et al. JAMA, 2009 Nov;302:2111-8; Benelli E et al. Ital J Pediatr, 2015 Feb;41:8). In addition, this mutation results in loss of the Sprouty domain, and R325* mutant protein lacked the ability to negatively regulate the Ras-MAPK pathway (Brems H et al. Nat. Genet., 2007 Sep;39:1120-6). This alteration is expected to result in loss of function by premature protein truncation. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at